CARGO is advancing a pipeline
of transformational next-generation
CAR T-cell therapies for cancer

3D molecule redering
  • CD34⁺ CD19⁻ CD22⁺ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies

    Bueno et al, Blood 2022

    Open PDF

  • CAR T-Cells With Dual Targeting of CD19 and CD22 in Adult Patients With Recurrent or Refractory B Cell Malignancies: A Phase 1 Trial

    Spiegel et al, Nature Medicine 2021

    Open PDF

  • Structural Details of Monoclonal Antibody M971 Recognition of the Membrane-Proximal Domain of CD22

    Ereno-Orbea et al, J. Biol Chem 2021

    Open PDF

  • Antigen-Independent Activation Enhances the Efficacy of 41BB Co-Stimulated CD22 CAR T-Cells

    Singh et al, Nature Medicine 2021

    Open PDF

  • CD22-Directed Car T-Cell Therapy Induces Complete Remissions in CD19-Directed Car–Refractory Large B-Cell Lymphoma

    Baird et al, Blood 2021

    Open PDF